Brodalumab

Active Crohn’s disease, clinically important active infections (e.g. active tuberculosis). Concomitant use with live vaccines.

Patient with history of Crohn’s disease, depression or suicidality, chronic or recurrent infection. Pregnancy and lactation.

Significant: Suicidal ideation and behaviour, serious infections and fungal infection, cryptococcal meningitis, exacerbation of Crohn’s disease.
Blood and lymphatic system disorders: Neutropenia.
Gastrointestinal disorders: Diarrhoea, nausea, oropharyngeal pain.
General disorders and admin site conditions: Fatigue.
Infections and infestations: Influenza, fungal infections including tinea infections (e.g. tinea pedis, tinea versicolor, tinea cruris), skin and mucosal candidiasis.
Injury, poisoning and procedural complications: Injection site reactions (e.g. erythema, pain, pruritus, bruising, haemorrhage).
Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.
Nervous system disorders: Headache.

Monitor for signs and symptoms of infections and signs of suicidal ideation or behaviour. Perform TB evaluation prior to initiation of therapy.

May increase serum concentration of midazolam.
Potentially Fatal: May diminish therapeutic and enhance adverse/toxic effects of live vaccines.

Description:
Mechanism of Action: Brodalumab is a recombinant human monoclonal (IgG2) antibody which selectively binds to with high affinity and antagonises the interleukin-17 receptor A (IL-17RA). It blocks the activity with cytokine IL-17RA IL-17A, IL-17F, IL-17A/F heterodimer and IL-25, leading to inhibition of cytokine-induced responses, including release of inflammatory cytokines and chemokines.
Pharmacokinetics:
Absorption: Bioavailability: Approx 55% (SC). Time to peak plasma concentration: Approx 3 days.
Distribution: Crosses placenta, enters breastmilk (small amounts). Volume of distribution: 8.9 ± 9.4 L.
Metabolism: Undergoes degradation via catabolic pathways into small peptides and amino acids.

Store between 2-8°C. Do not freeze. Protect from light. Stable for 14 days at room temperature (≤25°C).

Immunosuppressants

L04AC12 - brodalumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

Anon. Brodalumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 07/10/2019.

Buckingham R (ed). Brodalumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2019.

Joint Formulary Committee. Brodalumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/10/2019.

Siliq (Valeant Pharmaceuticals North America LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 07/10/2019.